This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record. Numerical trial results on this page are restricted to the results posted in the ClinicalTrials.gov record; calculations added by Clinical Biostats are labelled as such.
1. Trial at a Glance
This page covers the registry results for Pre-operative Treatment for Patients With Untreated Pancreatic Cancer (NCT03138720), a non-randomized phase 2 study. The primary outcome is CA 19-9 Normalization.
| Feature | Registry value |
|---|---|
| ClinicalTrials.gov identifier | NCT03138720 |
| Phase | Phase 2 |
| Condition | Resectable Pancreatic Cancer, Unresectable Pancreatic Cancer, Pancreatic Adenocarcinoma |
| Allocation | Non-Randomized |
| Design model | Single Group |
| Masking | None (open label) |
| Enrollment | 40 |
| Arms in the primary outcome | n/a |
| Lead sponsor | HonorHealth Research Institute |
| Results posted | Yes |
2. Clinical Question
The study asks whether a pre-operative treatment combination that includes paclitaxel protein bound, gemcitabine, cisplatin and paricalcitol can be evaluated in people with untreated pancreatic adenocarcinoma described as resectable, borderline resectable or locally advanced. The record’s brief summary frames the purpose as determining whether this combination is effective in individuals with resectable and unresectable pancreatic cancer. The primary outcome is CA 19-9 normalization after at least 3 treatment cycles.
The planned clinical context differs across the two cohorts. Cohort A includes participants with resectable pancreatic cancer. Cohort B includes participants with borderline resectable or locally advanced, unresectable pancreatic cancer. The registry says that protocol definitions determine cohort assignment, but those definitions are not reported in the registry record. Since the cohorts have different disease classifications, they are not interchangeable groups for estimating a treatment contrast.
The registry lists resectability rate, pathologic complete response, radiological response and overall survival among the secondary outcomes. These address additional aspects of disease status and outcomes, but the result values for them are not reported in the registry record in the information available for this analysis. The primary question therefore has a clearly stated biomarker endpoint, but its observed rate and precision cannot be assessed from the posted information. The record does not establish a comparison with another treatment or a control group, and it does not provide a basis for attributing changes in any outcome to the treatment combination.
3. Trial Design
NCT03138720 is listed as a phase II, completed, non-randomized, single-group study with no masking. The registry lists enrollment of 40. Its start date is 2017-05-23 and its primary completion date is 2023-07-13. These administrative details describe the study record; they do not establish how many participants contributed data to each outcome.
Participants were assigned to Cohort A if they had resectable pancreatic cancer, and to Cohort B if they had borderline resectable or locally advanced, unresectable pancreatic cancer. The record says cohort eligibility follows protocol definitions, which are not reported in the registry record. The arm descriptions say participants were offered up to 6 months of neoadjuvant therapy. The official title and brief summary identify paclitaxel protein bound, gemcitabine, cisplatin and paricalcitol as the treatment combination. The registry intervention listing names paclitaxel protein bound. The full treatment schedule and any additional dosing details are not reported in the registry record.
Because the study is non-randomized and has a single-group model, the cohorts are not randomized treatment arms and do not provide a like-for-like control comparison. Their disease classifications differ, so differences between cohort outcomes could reflect those differences as well as other factors. No separate comparator group is described. The record does not report the statistical analysis plan, allocation procedures within cohorts, eligibility details beyond the broad descriptions, or the sample-size justification. Completion status indicates the registry’s administrative status, not that every planned outcome has a posted numerical result.
4. Participant Flow and Accounting
The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.
Before assignment: n=8 participants did not meet inclusion/exclusion criteria for the following reasons: High bilirubin (n=2); Metastatic disease (n=3); Normal CA 19-9 (n=1); Normalized CA 19-9 (n=1); Withdrew consent (n=1).
Overall Study
| Stage | Cohort A: Resectable | Cohort B: Borderline Resectable/Locally Advanced (Unresectable) |
|---|---|---|
| STARTED | 10 | 22 |
| COMPLETED | 10 | 22 |
| NOT COMPLETED | 0 | 0 |
5. Baseline Characteristics
The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.
| Characteristic | Unit | Cohort A: Resectable | Cohort B: Borderline Resectable/Locally Advanced (Unresectable) | Total |
|---|---|---|---|---|
| Participants analysed | 10 | 22 | 32 | |
| Age, Continuous | Years | 67 (60.2 to 84.8) | 70.1 (49.3 to 83.3) | 69.4 (49.3 to 84.8) |
| Sex: Female, Male: Female | Participants | 6 | 8 | 14 |
| Sex: Female, Male: Male | Participants | 4 | 14 | 18 |
| Race (NIH/OMB): American Indian or Alaska Native | Participants | 0 | 1 | 1 |
| Race (NIH/OMB): Asian | Participants | 1 | 0 | 1 |
| Race (NIH/OMB): Native Hawaiian or Other Pacific Islander | Participants | 0 | 0 | 0 |
| Race (NIH/OMB): Black or African American | Participants | 0 | 0 | 0 |
| Race (NIH/OMB): White | Participants | 9 | 21 | 30 |
| Race (NIH/OMB): More than one race | Participants | 0 | 0 | 0 |
| Race (NIH/OMB): Unknown or Not Reported | Participants | 0 | 0 | 0 |
| Ethnicity (NIH/OMB): Hispanic or Latino | Participants | 0 | 2 | 2 |
| Ethnicity (NIH/OMB): Not Hispanic or Latino | Participants | 10 | 20 | 30 |
| Ethnicity (NIH/OMB): Unknown or Not Reported | Participants | 0 | 0 | 0 |
| Region of Enrollment: United States | Participants | 10 | 22 | 32 |
| Karnofsky Performance Status (KPS): 100% | Participants | 3 | 3 | 6 |
| Karnofsky Performance Status (KPS): 90% | Participants | 6 | 9 | 15 |
| Karnofsky Performance Status (KPS): 80% | Participants | 1 | 10 | 11 |
| Primary Tumor Site, Pancreas: Head | Participants | 5 | 14 | 19 |
| Primary Tumor Site, Pancreas: Neck | Participants | 3 | 6 | 9 |
| Primary Tumor Site, Pancreas: Body | Participants | 1 | 2 | 3 |
| Primary Tumor Site, Pancreas: Tail | Participants | 1 | 0 | 1 |
| Pancreatic Cancer Stage: IA | Participants | 4 | 2 | 6 |
| Pancreatic Cancer Stage: IB | Participants | 4 | 8 | 12 |
| Pancreatic Cancer Stage: IIA | Participants | 0 | 3 | 3 |
| Pancreatic Cancer Stage: IIB | Participants | 2 | 2 | 4 |
| Pancreatic Cancer Stage: III | Participants | 0 | 7 | 7 |
| CA 19-9 | U/mL | 115 (49 to 761) | 312 (45 to 3797) | 182 (35 to 3797) |
6. Primary Endpoint
The registry lists the primary outcome as CA 19-9 Normalization, measured over From enrollment to the end of treatment, up to 26 weeks..
| Element | Registry entry |
|---|---|
| Result type | Number |
| Measure of spread | 95% Confidence Interval |
| Unit | Percentage of participants |
| Endpoint classification | Binary Endpoint |
The primary outcome is CA 19-9 normalization, reported as a percentage of participants. CA 19-9 is described in the registry as a circulating tumor biomarker. Measurements were collected after every treatment cycle, approximately 3 weeks per cycle, and the outcome concerns normalization after 3 or more cycles. Its timeframe extends from enrollment to the end of treatment, up to 26 weeks.
As a general statistical matter, a biomarker normalization rate describes the proportion of participants meeting a defined laboratory criterion during a specified assessment period. It can provide a measurable intermediate outcome when laboratory values are collected repeatedly. It is not itself the same as a clinical outcome such as resection, pathologic response or survival. Interpretation depends on the operational definition of “normalization,” the denominator used, and how participants without an evaluable measurement are handled. The specific laboratory threshold, analysis population and missing-measurement rules are not reported in the registry record.
The record specifies a 95% Confidence Interval as the dispersion measure for this outcome, but it does not report the observed percentage or interval bounds. Consequently, neither the rate nor its statistical precision can be described from the posted information available for this analysis.
7. Why No Re-analysis Is Shown
8. Statistical Interpretation
The registry record identifies CA 19-9 normalization after 3 or more cycles as the primary outcome and specifies a 95% Confidence Interval. However, it does not report the observed normalization percentage or the confidence interval limits. There is therefore no posted primary-outcome estimate to interpret, and no basis for describing how common normalization was or how precisely it was estimated.
The study enrolled 40 according to the registry record, but that enrollment figure should not be assumed to be the denominator for the primary outcome. The number of participants assessed for CA 19-9, the number who received at least 3 cycles, and the number included in the primary analysis are not reported in the registry record. Without these details, the relationship between enrollment and the endpoint analysis is unknown.
The study’s structure also limits what can be inferred from any cohort-specific outcome. It is non-randomized and single-group, and the cohorts correspond to different disease classifications. There is no randomized control group for estimating a treatment contrast. A change in biomarker status, if observed, could not by itself establish that the treatment caused that change. General considerations such as disease course, participant selection, treatment exposure and measurement timing can affect observed outcomes in a single-group study.
The registry lists several secondary outcomes, including resectability, pathologic complete response, radiological response and overall survival. Their numerical findings are not reported in the registry record in the information available for this analysis. The existence of listed outcomes should not be taken as evidence that a particular result was observed.
The posted safety entries give cohort-specific numbers at risk and affected for serious and other adverse events, along with deaths and selected serious-event terms. These entries can be described as reported counts, but they do not by themselves establish that an event was caused by treatment. The record does not report the event-attribution rules, exposure-adjusted rates, or details needed to determine the duration of follow-up for these counts.
Overall, the record supplies the broad design, endpoint definition and selected safety counts, but not the primary outcome estimate or most outcome results. Statistical interpretation must therefore focus on what is defined and what remains unreported, rather than on a treatment-effect conclusion.
9. Statistical Methods Explained
The registry describes the primary outcome as a percentage of participants and specifies a 95% Confidence Interval. The numerical estimate and interval are not reported in the registry record. The methods below explain how such statistics are generally interpreted; they do not identify an analysis method used in this study unless the record states it.
What does a percentage estimate describe?
As a general statistical explanation, a percentage for a binary outcome represents the share of an analyzed group that meets the outcome definition. For CA 19-9 normalization, the event is normalization after 3 or more treatment cycles. Interpretation requires knowing both the number meeting that criterion and the denominator included in the analysis. The registry record does not report those counts or define the endpoint’s laboratory threshold. It also does not state how participants who stop treatment early or lack a measurement are handled.
A percentage can be clinically understandable, but its meaning depends on the population and assessment period. The stated timeframe runs from enrollment to the end of treatment, up to 26 weeks, and measurements were collected after every cycle, approximately 3 weeks per cycle. The record does not report whether every participant had the same number of measurements or whether the analysis used a particular visit or the most favorable measurement.
How should a confidence interval be read?
In general, a confidence interval expresses uncertainty around an estimate under the assumptions of the method used to calculate it. A narrower interval indicates greater statistical precision than a wider interval, while neither width nor location can be evaluated without the interval bounds. The registry specifies a 95% Confidence Interval for the primary outcome, but gives no bounds or calculation method. The interval therefore cannot be used to assess precision.
A confidence interval is not a guarantee about an individual participant’s outcome, and it does not address all sources of bias. In a non-randomized, single-group study, an interval around an outcome percentage would describe sampling uncertainty under its analysis assumptions; it would not remove confounding or create a comparison group. The analysis population and assumptions are not reported in the registry record.
What can be learned from a single-group design?
As a general point, a single-group study can describe outcomes among participants who receive a treatment, subject to the study’s measurement and follow-up procedures. It does not directly estimate what would have happened to comparable participants under a different treatment or no treatment. Random assignment is not reported, and the registry explicitly classifies allocation as non-randomized. The two cohorts also differ by disease classification, so comparisons between them would not constitute a randomized treatment comparison.
The record’s sample-size assumptions describe planning illustrations based on an observed effect, using a two-sided significance level of 0.05, equal allocation between two arms and a normal approximation. It also distinguishes total-event planning for time-to-event outcomes from participants per arm for other outcomes. These are illustrative planning assumptions, not a description of this trial’s single-group design. The actual illustration values and the trial’s own sample-size justification are not reported in the registry record. Such illustrations are not observed power and should not be read as evidence that a result is likely or established.
Why does over-dispersion matter in general?
For outcomes counted across participants or over time, some statistical models assume a particular relationship between the mean and the variability. In general, over-dispersion means the observed variability is greater than that assumed by a model. If it is ignored, uncertainty estimates can be too small, which may make results appear more precise than they are. This concept is relevant only if the outcome and analysis use a model with such an assumption. The registry record does not report the primary-outcome model, a dispersion assessment, or whether over-dispersion was considered. The primary endpoint is described as a percentage, and no model details are given.
What is not established by the posted analysis information?
The record does not report the statistical analysis plan, the exact method for calculating the confidence interval, prespecified subgroup analyses, interim analyses, or rules for handling missing outcome data. It lists 11 outcome measures and 14 analyses, but does not report how those analyses were organized or whether multiplicity adjustments were used. Without those details and the numerical outcome results, the strength and precision of findings cannot be judged. General statistical principles can clarify what the measures would mean, but they cannot substitute for the absent estimates and analysis details.
10. Multiplicity, Missing Data and Analysis Populations
The registry lists 11 outcome measures and 14 analyses. It identifies CA 19-9 normalization as the primary outcome and lists resectability rate, pathologic complete response, radiological response and overall survival among the secondary outcomes. The registry record does not report a multiplicity strategy, such as a prespecified hierarchy among outcomes or an adjustment to account for multiple statistical tests. As a general statistical matter, examining multiple outcomes can increase the chance of finding an apparently notable result by chance if each is interpreted without regard to the others. The extent of that issue cannot be assessed from the outcome list alone.
The primary endpoint is defined for assessment after 3 or more cycles, but the record does not state how missing laboratory measurements, early treatment discontinuation, or participants without enough cycles were handled. It also does not report imputation methods, sensitivity analyses for missing data, or the number of participants with evaluable primary-outcome measurements. These omissions prevent assessment of whether the reported analysis, if any, represents all enrolled participants or a subset with available measurements.
The record does not specify analysis populations such as an intention-to-treat population, a treated population or an evaluable population. Enrollment is listed as 40, but the connection between that figure and the denominators for each outcome is not reported. The registry record also does not describe interim analyses or stopping rules. These details matter for understanding how outcomes were selected, which participants contributed data and how uncertainty should be interpreted; they cannot be inferred from the study’s phase or completion status.
11. Safety Results
The registry reports serious adverse events as affected participants divided by participants at risk.
| Arm | Participants with serious adverse events | Participants at risk | Percentage |
|---|---|---|---|
| Cohort A: Resectable | 3 | 10 | 30.0% |
| Cohort B: Borderline Resectable/Locally Advanced (Unresectable) | 11 | 22 | 50.0% |
Deaths
| Arm | Deaths (participants affected of at risk) |
|---|---|
| Cohort A: Resectable | 3 of 10 |
| Cohort B: Borderline Resectable/Locally Advanced (Unresectable) | 14 of 22 |
Other (non-serious) adverse events
Participants with at least one non-serious event at or above the registry's 0% reporting threshold.
| Arm | Participants affected of at risk |
|---|---|
| Cohort A: Resectable | 10 of 10 |
| Cohort B: Borderline Resectable/Locally Advanced (Unresectable) | 22 of 22 |
Most frequent serious adverse event terms
| Event term | Organ system | Cohort A: Resectable | Cohort B: Borderline Resectable/Locally Advanced (Unresectable) |
|---|---|---|---|
| Blood Antidiuretic Hormone Abnormal | Investigations | 1 of 10 | 1 of 22 |
| Duodenal Hemorrhage | Gastrointestinal disorders | 0 of 10 | 2 of 22 |
| Anal Pain | Gastrointestinal disorders | 1 of 10 | 0 of 22 |
| Anemia | Blood and lymphatic system disorders | 1 of 10 | 0 of 22 |
| Stroke | Nervous system disorders | 0 of 10 | 1 of 22 |
| Constipation | Gastrointestinal disorders | 0 of 10 | 1 of 22 |
| Other - Biliary Obstruction | Hepatobiliary disorders | 0 of 10 | 1 of 22 |
| Biliary Tract Infection | Infections and infestations | 0 of 10 | 1 of 22 |
| Ankle Fracture | Injury, poisoning and procedural complications | 0 of 10 | 1 of 22 |
| Sepsis | Infections and infestations | 0 of 10 | 1 of 22 |
Most frequent non-serious adverse event terms
| Event term | Organ system | Cohort A: Resectable | Cohort B: Borderline Resectable/Locally Advanced (Unresectable) |
|---|---|---|---|
| Platelet Count Decreased | Investigations | 8 of 10 | 17 of 22 |
| Peripheral Sensory Neuropathy | Nervous system disorders | 6 of 10 | 18 of 22 |
| Hypomagnesemia | Metabolism and nutrition disorders | 6 of 10 | 17 of 22 |
| Anemia | Blood and lymphatic system disorders | 5 of 10 | 15 of 22 |
| Alopecia | Skin and subcutaneous tissue disorders | 6 of 10 | 14 of 22 |
| Diarrhea | Gastrointestinal disorders | 6 of 10 | 12 of 22 |
| Fatigue | General disorders | 4 of 10 | 13 of 22 |
| Hypokalemia | Metabolism and nutrition disorders | 7 of 10 | 10 of 22 |
| Edema Limbs | General disorders | 3 of 10 | 13 of 22 |
| Dehydration | Metabolism and nutrition disorders | 4 of 10 | 12 of 22 |
Serious events with the highest arm-level rate: anal pain (10.0%), anemia (10.0%), blood antidiuretic hormone abnormal (10.0%), duodenal hemorrhage (9.1%), stroke (4.5%).
The serious adverse event entries list Cohort A with 10 participants at risk and 3 affected, and Cohort B with 22 at risk and 11 affected. The record also lists 3 deaths for Cohort A and 14 for Cohort B. For other adverse events, it lists 10 at risk and 10 affected in Cohort A, and 22 at risk and 22 affected in Cohort B. These are registry counts; the record does not provide enough detail to establish a causal relationship between an event and treatment.
The listed serious-event terms include Anal Pain at 10.0%, Anemia at 10.0%, Blood Antidiuretic Hormone Abnormal at 10.0%, Duodenal Hemorrhage at 9.1%, Stroke at 4.5% and Constipation at 4.5%. These percentages should be read as the registry’s reported entries, not as a complete safety profile. The information does not describe event severity grading beyond the serious-event classification, timing, duration, recurrence, or attribution to study treatment. It also does not explain whether participants could contribute more than one event term or how the percentages were calculated.
The adverse-event denominators differ from the listed enrollment of 40, and the reason is not reported in the registry record. Counts and percentages should therefore be interpreted within their stated cohort entries rather than treated as full-study rates or compared as if cohorts were randomized groups. Deaths listed in a cohort are not, by themselves, evidence that those deaths were treatment-related.
12. What the Result Does, and Does Not, Mean
The record establishes that NCT03138720 was a completed, phase II, non-randomized, single-group study with cohorts defined by pancreatic cancer resectability status. It identifies a pre-operative treatment combination in the study title and summary, and defines CA 19-9 normalization after at least 3 cycles as the primary outcome. It also lists several secondary outcomes and reports selected adverse-event counts and terms.
What the posted information does not establish is the primary outcome result. The normalization percentage and 95% Confidence Interval are not reported in the registry record. Numerical results for the listed secondary outcomes are also not reported in the information available for this analysis. Therefore, the posted record as described does not permit a conclusion about the observed CA 19-9 normalization rate, its precision, or the outcomes for resection, pathological response, radiological response or survival.
Even if outcome estimates were available, a single-group non-randomized design would not by itself show what would have occurred under an alternative treatment. The cohorts represent different disease classifications and are not a randomized comparison. Any cohort contrast would need to be interpreted with that distinction in mind. An observed biomarker change would also not automatically establish a corresponding clinical benefit; the biomarker endpoint and the listed clinical outcomes are different measures.
The safety counts describe events reported in the registry, but do not establish causation or provide all the context needed to compare risks. In general, event counts need denominators, follow-up information and clear attribution rules to be interpreted as rates or treatment-related harms. Some denominator information is present, while follow-up and attribution details are not reported in the registry record.
Thus, the record supports a description of the study’s design, intended outcome and some safety reporting, but it does not support a treatment-effect conclusion. Missing numerical outcome estimates and analysis details are central to that limitation.
13. Why This Trial Matters Statistically
This study illustrates why a clearly defined endpoint is not enough to evaluate a clinical result. The registry specifies CA 19-9 normalization, its assessment after 3 or more cycles, a treatment-period timeframe of up to 26 weeks, and a 95% Confidence Interval. Yet the numerical percentage and interval are not reported in the registry record. Without the estimate, readers cannot assess either the observed frequency or its statistical precision.
It also highlights the distinction between a treatment cohort and a control group. The study is non-randomized and single-group, with cohorts based on resectability classification. Those cohorts describe different clinical groups; they are not like-for-like randomized controls. This matters statistically because observed outcomes in a treated group do not directly show the outcome that would have occurred under another treatment or without treatment.
Another important feature is the difference between an endpoint’s definition and its analysis specification. The record names a biomarker outcome and a confidence-interval measure, but does not report the method for calculating the interval, the analysis population, or how missing measurements were handled. These details influence how readers should understand the estimate and who it represents.
Finally, the safety entries show why counts require context. The record includes cohort-specific denominators, affected counts, deaths and selected event terms, but does not report all information needed to interpret attribution, timing or follow-up. Statistical literacy means recognizing both the useful descriptive information and the limits of what it can establish. In this record, the design and outcome definitions are visible, while the primary outcome result and key analytic details are not reported.
14. Limitations
- The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
- Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.
The most direct limitation is that the primary outcome’s numerical result is not reported in the registry record. Although the endpoint is described as a percentage with a 95% Confidence Interval, neither the estimate nor interval limits are available. The registry record also does not report numerical results for the listed secondary outcomes in the information available for this analysis. Consequently, outcome magnitude and precision cannot be assessed.
The record lists enrollment of 40, but does not report how many participants were eligible for the primary analysis, received enough treatment cycles for assessment, or had evaluable CA 19-9 measurements. The endpoint’s laboratory threshold and rules for missing measurements are not reported. These gaps leave the analysis denominator and potential impact of missing data unclear.
The non-randomized, single-group design has no described control group. Cohort membership reflects resectability classification, with protocol definitions not reported in the registry record. Cohort outcomes therefore cannot be treated as a randomized comparison of treatment effects. The record also does not provide the full statistical analysis plan, sample-size justification, interim-analysis details, or multiplicity strategy.
Safety interpretation is limited by the absence of reported details on event attribution, timing, duration and follow-up. Although cohort-specific adverse-event counts and selected terms are listed, the record does not explain why adverse-event denominators differ from the overall enrollment figure. The available safety entries should not be assumed to represent a complete or exposure-adjusted comparison.
15. Related Tutorials
16. Related Statistical Calculators
17. Sources
- ClinicalTrials.gov: Pre-operative Treatment for Patients With Untreated Pancreatic Cancer — NCT03138720.
- Registry record last updated 2026-04-22; status last verified 2026-01.
- Results first posted 2026-04-22.
- Data retrieved from ClinicalTrials.gov on 2026-11-09.
- Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.
Continue through the Clinical Biostats statistical pathway
Use this trial's endpoint as a starting point for deeper study of effect measures, confidence intervals, and sample-size planning.
18. Record Summary
NCT03138720 is a completed phase II, non-randomized, single-group study with enrollment listed as 40. It evaluates pre-operative treatment in cohorts described as resectable and borderline resectable or locally advanced, unresectable pancreatic cancer. The study title and summary describe a combination including paclitaxel protein bound, gemcitabine, cisplatin and paricalcitol.
The primary outcome is CA 19-9 normalization after 3 or more cycles, assessed from enrollment to the end of treatment, up to 26 weeks. The registry specifies a 95% Confidence Interval but does not report the primary result or interval. Secondary outcomes include resectability, pathologic complete response, radiological response and overall survival; their numerical results are not reported in the information available for this analysis.
The record lists cohort-specific serious and other adverse-event counts, deaths and selected serious-event terms. It does not report the full analysis plan, missing-data rules, multiplicity strategy or event-attribution details. The design and endpoint can be described, but the posted information does not support a treatment-effect conclusion.